MC240502: Cancer CARE (Connected Access and Remote Expertise) Beyond Walls In-home iNtraVesIcal ThErapy (INVITE) Study - A Phase Ib/II, Single-Arm Trial of Delivering Intravesical Therapy for Bladder Cancer in Patients' Homes
Latest Information Update: 15 Apr 2026
At a glance
- Drugs Docetaxel (Primary) ; BCG vaccine; Gemcitabine; Mitomycin
- Indications Bladder cancer
- Focus Adverse reactions
- Acronyms INVITE
Most Recent Events
- 30 Mar 2026 Planned End Date changed from 6 Jun 2026 to 31 Dec 2026.
- 30 Mar 2026 Planned primary completion date changed from 6 Jun 2026 to 31 Dec 2026.
- 23 Apr 2025 Status changed from not yet recruiting to recruiting.